natgillin/translations-raw huggingface dataset:
The method according to claim 18, wherein the method includes the step of applying an initial pulling force to the envelope until a portion of the envelope breaks within the outer cable sheath, prior to pulling the remaining portion of the envelope from the opposite end of the outer cable sheath. 
Postupak sukladno zahtjevu 14, uključujući korak podvrgavanja omotnice (8) vučnoj sili dok se dio omotnice ne slomi unutar vanjskog plašta (6), i to prije povlačenja preostalog dijela omotnice (8) iz nasuprotnog kraja vanjskog plašta (6).
number of marbles buried 
Broj međunarodne objave:
A process for preparing a compound of formula (I) 
Postupak pripreme spoja formule (I) iša
The solid was washed with water and 1,2-dichloroethane and dried. 
Krutina se ispere s vodom i 1,2-dikloroetanom i osuši.
A method of manufacturing a composition for prophylaxis and treatment of malaria comprising: mixing a malaria prophylaxis or malaria treatment-effective amount of a dispiro 1,2,4-trioxolane, its prodrugs and optical isomers thereof, with a pharmaceutically acceptable carrier, said trioxolane being selected from the group consisting of: compounds of formula (I) Wherein R selected from: pharmaceutically acceptable salts, and combinations of the same. 
Postupak za proizvodnju pripravka za profilaksu 1 liječenje malarije koji obuhvaća: miješanje one količine dispiro- 1,2,4-trioksolana koja predstavlja efektivnu dozu za profilaksu malarije ili za liječenje malarije, njegovih prolijekova 1 optičkih izomera, sa farmaceutski prihvatljivim nosačem, pri čemu je navedeni trioksolan izabran 12 grupe koju čine: spojevi formule (1) ALE kO "= &
An appliance according to claim 7, wherein said motor is also operable to actuate the door to move to the closed position. 
Uređaj u skladu s patentnim zahtjevom 7, naznačen time što navedeni motor (137) također radi na takav način da aktuira vrata kako bi se pomaknula u zatvoreni položaj.
represents a hydrogen atom, a C1-4 alkoxy carbonyl group, a C3-6 cycloalkyl carbonyl group, a benzoyl group, a C1-6 alkyl group, the groups being optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group or a C1-4 alkoxy group; o and m represent 1 to 2; n represents 0 to 3; 
R4 predstavlja atom vodika, C,4 alkoksikarbonilnu skupinu, C3.g cikloalkilkarbonilnu skupinu, benzoilnu skupinu, Cig alkilnu skupinu, gdje su te skupine izborno supstituiran s 1 do 4 supstituenta, koje se bira između atoma halogena, hidroksilne skupine ili C,4 alkoksi skupine; oim znače 1 do 2; n znači 0 do 3; pznači 0 do 2;i q znači 0 do 2.
The pharmaceutical composition according to claim 1 which is in form of a transdermal therapeutic system. 
Metoda prema zahtjevu 11, naznačena time da je farmaceutski sastav u obliku transdermalnog terapeutskog sustava.
Background of the invention 
Stanje tehnike
a variable heavy chain having at least 75% amino acid sequence identity to SEQ ID NOs: 25, 26, 27 and 28; and (b) a variable light chain having at least 75% amino acid sequence identity to SEQ ID NOs: 30, 31 and 32; and 
Protutijelo ili njegov za antigen vezni fragment prema zahtjevu 4 ili 5, gdje je protutijelo ili fragment humanizirano i ima varijabilni teški lanac s barem 75% aminokiselina identičnih aminokiselinskoj sekvenci u SEQ ID NO:25, 26, 27 ili 28.
In certain embodiments, the Fc domain of the polypeptide may be from an IgG, IgM, IgD, IgE, or IgA. 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-7, gdje je Ig Fc domen izveden iz IgG, IgM, IgD, IgE, ili IgA.
The use of a composition according to claim 7 or claim 9 or claim 10, or the composition for use in a method according to any one of claims 8 to 10, wherein the composition is provided in unit dose form and comprises 0.5mg to 1g of the compound. 
Uporaba smjese prema patentnom zahtjevu 7 ili patentnom zahtjevu 9 ili patentnom zahtjevu 10, ili smjesa za uporabu u metodi prema bilo kojem od patentnih zahtjeva 8 do 10, naznačena time, što se smjesa osigurava u obliku jedinične doze 1 sadrži 0.5 mg do 1 g spoja.
The composition for use of any of claims 1-5; wherein (a) the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of Blautia wexlerae; or wherein (b) the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:3 or 4; wherein according to (b), preferably the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:4, or the bacterial strain has the 16s rRNA sequence represented by SEQ ID NO:4. 
Sastav za upotrebu prema bilo kojem od zahtjeva 1-5; pri čemu (a) soj bakterije ima sekvenciju 16s rRNK koja je bar 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% jednaka sa sekvencijom 16s rRNK soja bakterije Blautia wexlerae; ili pri čemu (b) soj bakterije ima sekvenciju 16s rRNK koja je bar 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% jednaku sa SEQ ID NO:3 ili 4; gdje prema (b), poželjno soj bakterije ima sekvenciju 16s rRNK koja je bar 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% jednaka sa SEQ ID NO:4, ili soj bakterija ima sekvenciju 16s rRNK predstavljenu sa SEQ ID NO:4.
The method of any of [1]-[12] wherein the oligonucleotide comprises a downstream element at its 3' terminus which is complementary to the target sequence and which is not a polymerase substrate. 
Komplet iz bilo kog prethodnog patentnog zahtjeva pri čemu taj oligonukleotid još obuhvaća nizvodni element na svom 3' terminusu koji je komplementaran ciljnoj sekvenci i koji nije supstrat polimeraze.
• the wall of the container has a moisture content of from 1850 ppm to 1930 ppm when exposed to ambient conditions for 4 days. 
. zid posude ima sadržaj vlage od 1850 ppm do 1930 ppm kada je izložen ambijentalnim uvjetima tijekom 4 dana.
A method of preparing a compound of formula (I): 
Postupak dobivanja spoja formule (I):
Nitric oxide (NO) is one of the smallest and simplest of the biologically active molecules in nature. 
Dušikov oksid (NO) je jedna od najmanjih i najjednostavnijih biološki aktivnih molekula u prirodi.
A combination according to claim 8 wherein the active compound (c) is selected from the group consisting of (a) B2-agonists and (b) cortiocosteroids. 
Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatni spoj (c) odabran iz skupine koju čine (a) B2-agonisti i (b) kortikosteroidi.
Method according to claim 1, wherein the weak Lewis-acid comprises copper aluminum chloride (Cu[AlCl4]). 
Postupak prema zahtjevu 1, naznačen time da slaba Lewisova kiselina sadrži bakrov aluminijev klorid (Cu[AlCL]).
The solid oral extended release pharmaceutical dosage form of anyone of claims 1 to 8, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3, preferably equal to or less than about 1.19 g/cm3. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, 2 ili 3, naznačen time da je formulacija matrice s produljenim otpuštanjem otporna na rad od barem oko 0.06 J bez pucanja.
The compounds of claim 1 wherein R4 is phenyl substituted with one to three R41 substituents independently selected from the group consisting of (C1-3)alkyl, (C1-3)alkoxy, phenyl(C1-3)alkoxy, hydroxy, C1-6alkylaminocarbonyl, and aminocarbonyl; provided that no more than one R41 substituent is aminocarbonyl, C1-6alkylaminocarbonyl, hydroxy, or a phenyl-containing substituent. 
Spoj prema zahtjevu 1 naznačen time da R" je fenil supstituiran sa jednim do tri R"' supstituenta nezavisno izabrana iz skupine koju čine (Crs)alkil, (Crg)alkoksi, feni(C,.)alkoksi, hidroksi, C,salkilaminokarbonil i aminokarbonil; uz uvjet da ne više od jedan R"' supstituent je aminokarbonil, C, galkilaminokarbonil, hidroksi ili supstituent koji sadrži fenil.
Plastic flooring of PVC (Toro EL available form Tarkett AB Sweden) with “vertical conductive channels” containing carbon black. 
3) ču, plastični pod (Toro EL dostupan od tvrtke Tarkett AB Å vedska) s "vertikalno vodljivim kanalima" koje sadrže ađu.
A combination for use according to claim 11 wherein the disorder mediated by inappropriate Pl3-kinase activity is asthma. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću P13-kinaze astma.
Two values of a may then be calculated by the relationships: EPMATHMARKEREP EPMATHMARKEREP The value of a for the material may then be calculated as the mean of all the measured values of a, e.g. of a1 and a2. 
-1x>n(PĆ) (PP) Vrijednost a za taj materijal se može tada izračunati kao srednja vrijednost svih izmjerenih veličina a, na primjer, a i
It should be noted that the stereo image comprises at least two images of a person of the two-dimensional image and in that the stereo image comprises images based on the two-dimensional image at least two different angles with respect to the person in the two-dimensional image. 
Identifikacijski dokument (1) prema zahtjevu 1, gdje fantomska slika (D) sadrži najmanje dvije slike osobe sa dvodimenzionalne slike (A), i gdje je fantomska slika (D) izrađena iz dva različita kuta u odnosu na osobu sa dvodimenzionalne slike.
removing the formed insulation block from the mould. 
nastali izolacijski blok se hladi, i -
the maximum coding unit of the maximum coding units is hierarchically split into the coding units including a coding unit of a current depth and a coding unit of a depth greater than the current depth, 
određivanje barem jedne jedinice predviđanja koja je razdvojena iz jedinice kodiranja koristeći informacije o jedinici predviđanja, pri čemu je informacija o jedinici predviđanja raščlanjena iz toka bitova;
An adenovirus according to claim 15, wherein the reporter gene is sodium iodide symporter, intracellular metalloproteins, HSV1-tk, GFPs, luciferase or oestrogen receptor. An adenovirus according to claim 1, wherein BX is a bond. 
Adenovirus u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što je transgen reporterski gen, primjerice natrijsko-jodidni simporter, unutarstanični metaloproteini, HSV1-tk, GFPs, luciferaza ili estrogenski receptor.
The method of claim 1 wherein the first set of components comprises alumina particles with an average particle size greater than 1 mm. 
Metoda iz bilo kojeg od patentnih zahtjeva 1-5 pri čemu prvi set komponenata obuhvaća čestice aluminija prosječne veličine čestica veće od 1 mm.
In a preferred embodiment, said effective amount is less than about 15 milligrams of aminopyridine. 
Sastav prema zahtjevu 2, naznačen time da je spomenuti sastav primijenjen dvaput dnevno u dozi od 10 miligrama aminopiridina.
The distributed computing system of any one of the claims 9 to 11, wherein the encoder (11) is adapted to use, for each first data-subset to be encoded, a k x li-Beta random number matrix, where li corresponds to the number of elements of the ith first data-subset and li is less than m, 
Distribuirani računalni sustav u skladu s bilo kojim od patentnih zahtjeva 9 do 11, naznačen time - što je koder (11) podešen za upotrebu, za svaki prvi podatkovni podniz koji treba kodirati, k x L-Beta matrice slučajnih brojeva, gdje l; odgovara broju elemenata iz i-tog prvog podatkovnog podniza, gdje je l; manji od m;
The composition of claim 9, wherein the second pharmaceutical agent is selected from the group consisting of donepezil, galantamine, memantine, rivastigmine, and tacrine. 
Pripravak u skladu s patentnim zahtjevom 9, naznačen time što drugo farmaceutsko sredstvo se bira iz skupino koju čine donepezil, galantamin, memantine, rivastigmin, te takrin.
Through these features, a pattern of runner channels can be created, having, compared with the known small channels, a lesser number as well as a greater cross section and more robust shape, with which in a relatively short time a relatively large surface can be covered and soaked, while those runner channels, after soaking the reinforcement package to a sufficient extent, can be pushed away substantially without leaving a trace, thus resulting in an optimum appearance. 
S tim značajkama mogu se dobiti strukture protočnih kanala, koje su u usporedbi s poznatim malim kanalima prisutne u manjem broju, a također imaju i veći poprečni presjek i mnogo veći oblik, s kojim se u relativno kratkom vremenu može pokriti i nakvasiti relativno veliku površinu, dok se ti protočni kanali, kad se tijelo za ojačanje nakvasi do dovoljne mjere, mogu odgurnuti uglavnom bez ostavljanja tragova, što ima za posljedicu optimalan izgled.
The tablet of claim 1, wherein the pharmaceutical composition provides a width at 50% of the height of a mean plasma concentration/time curve of the metformin from about 1.0 to about 10 hours or a width at 25% of the height of mean plasma concentration/time curve of the metformin from about 0.25 to about 14 hours. 
Farmaceutski sastav sukladno bilo kojem od zahtjeva 1 - 6, pri čemu farmaceutski sastav osigurava širinu za 50% krive srednja koncentracija u plazmi/vrijeme metformina od oko 0.25 do oko 14 sati.
A pharmaceutical composition according to claim 12 for use in the treatment or prevention of a condition selected from the group consisting of cardiac disorders and diseases, muscle fatigue, musculoskeletal disorders and diseases, CNS disorders and diseases, cognitive dysfunction, bone disorders and diseases, malignant hyperthermia, diabetes, sudden cardiac death, and sudden infant death syndrome, or for improving cognitive function. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time, da se koristi u liječenju ili prevenciji stanja odabranih is skupine koja se sastoji od srčanih poremećaja i oboljenja, mišićnog umora, poremećaja i bolesti muskuloskeletalnog sustava, poremećaja i bolesti središnjeg živčanog sustava (CNS), kognitivne disfunkcije, nervno-mišićnih poremećaja i oboljenja, poremećaja i bolesti kostiju, tumorske kaheksije, maligne hipertermije, dijabetesa, iznenadne srčane smrti i sindroma iznenadne dječje smrti ili za poboljšanje kognitivne funkcije.
The waste trap (10) of claim 7, wherein the insert (40) is at least one of: releasably and sealingly attachable to the internal surface (52) of the sleeve (22). 
Sifon (10) prema patentnom zahtjevu 7, gdje je umetak (40) najmanje jedan: sa sposobnošću odvajanja i zaptivanja na unutrašnju površinu (52) naglavka (22).
The derivative of any one of claims 62-64, wherein said second antibacterial agent is rifampin, clarithromycin, mupirocin, azithromycin, fusidic acid, or vancomycin. 
Derivat prema zahtjevu 5, gdje je drugo antibakterijsko sredstvo rifampin, klaritromicin, mupirocin, azitromicin, fuzidična kiselina ili vankomicin.
After stirring at room temperature for 45 minutes, water (234 ml) was added and the mixture extracted with ether (2 x 200 ml). 
Nakon miješanja na sobnoj temperaturi tijekom 45 minuta, doda se voda (234 ml) 1 smjesa se ekstrahira eterom (2 x 200 ml).
is a nucleofugic group or an optionally substituted aliphatic, aromatic, or heteroaromatic group; and each of R4 and R5, independently, is an optionally substituted aliphatic, aromatic, or heteroaromatic group, or R4 and R5, taken together with the intervening oxygen and boron atoms, form an optionally substituted 5- to 10-membered ring having 0-2 additional ring heteroatoms selected from N, O, or S; 
R? je nukleofugalna grupa ili izborno supstiluirana alifalična, aromatična ili heteroaromatična grupa; i svako R* i R?, nezavisno, je izborno supstituirana alifatična, aromatična ili heteroaromatična grupa, ili R' i R', uzeti zajedno sa atomima kisika i bora koji se nalaze između, formiraju izborno supstituirani 5- do 10-člani prsten koji ima 0-2 dodatna heteroatoma u prstenu izabrana od N, O ili S; navedeni postupak sadrži:
The disintegrants can be added to the other excipients according to the process used in the state of the art, either in the process of granulating and/or in the preparation of the compression mixture. 
Razgrađujuća sredstva mogu biti dodana drugim ekscipijensima u skladu sa postupkom koji se koristi u tehnici, bilo u postupku granulacije i/ili pripreme kompresijske smjese.
In a preferred embodiment of the process according to the invention, the aliphatic carboxylic acid(s) employed in step (b) are implemented in step (b) in the form of a melt. 
Postupak prema bilo kojem od zahtjeva 1 do 15, naznačen time da se C8 do C24 alifatska karboksilna kiselina odnosno alifatske karboksilne kiseline koje se koriste u koraku (b) primjenjuju u rastaljenom stanju.
Ar2 is phenyl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom, CN, SF5, cyclopropyl, a C1-C4 alkyl group, a C1-C4 alkoxy group and a fluoroC1-C4 alkyl group; 
Ar? je fenil, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se neovisno bira između atoma halogena, CN, SF, ciklopropila, C,-C4 alkilne skupine, Ci-Ca alkoksi skupine i fluorC;-C4 alkilne skupine;
To the same extent, the theory that oxidized LDL is responsible for some of the pathological features of atherosclerotic lesions derives from the findings in cultured cells systems that oxidized LDL causes cellular changes that correlate with known aspects of arterial lesions but are not induced by native LDL. 
Do neke mjese, teorija da je oksidirani LDL odgovoran za iste patološke značajke ateroskleroznih lezija potječe od nalaza u sistemima uzgajanih stanica da oksidirani LDL uzrokuje promjene stanica koje koreliraju s poznatim aspektima arterijskih lezija, ali nisu izazvane urođenim LDL.
The oligonucleotide-based compound of claim 5, wherein the modified oligonucleotide comprises at least one 2'-O-substituted nucleotide selected from the group consisting of 2'-O-methyl, 2'-O-methoxy, 2'-O-ethoxy, 2'-O-methoxyethyl, 2'-O-alkyl, 2'-O-aryl, and 2'-O-allyl. 
Spoj na bazi oligonukleotida prema zahtjevu 5, naznačen time da modificirani oligonukleotid sadrži barem jedan 2'-O-supstituiran nukleotid izabran iz grupe koja se sastoji od 2'-O-metil, 2'-O-metoksi, 2'-O-etoksi, 2'-O-metoksietil, 2'-O-alkil, 2'-O-aril, i 2'-O-alil.
A compound according to claim 12, wherein: 
Spoj prema patentnom zahtjevu 1, naznačen time što je spoj izabran od:
Only droplets may remain in the container, and it can therefore be considered fully emptied. 
U spremniku mogu zaostati samo kapljice, i on se stoga može smatrati potpuno ispražnjen.
Fig. 13 and Fig. 14 show a fourth embodiment in which the sealing member is an O-ring 11. 
Slika 13 i slika 14 prikazuju četvrto ostvarenje u kojemu je element za nepropusno zatvaranje prsten koji ima oblik O-prstena 11.
An isolated antibody which specifically binds human CD38 as set forth in SEQ ID NO:1 and cynomolgus CD38 as set forth in SEQ ID NO:2 comprising: 
Izolirano protutijelo koje specifično veže ljudski CD38 (SEQ ID NO: 1) i makaki CD38 (SEQ ID NO:2) koje sadrži:
The crematorium (10) of any preceding claim, wherein the tertiary chamber (24) comprises a detachable flue stack (26). 
Krematorij (10) iz bilo kojeg od prethodnih zahtjeva, pri čemu tercijarna komora (24) obuhvaća odvojivi dimnjak
The method according to claim 13, wherein the replacement component is subjected to a processing technique selected from the group consisting of machining, drilling and combinations thereof. 
Metoda prema zahtjevu 13, pri čemu se zamjenska komponenta dobiva strojnom obradom ili bušenjem ili kombinacijom ove dvije tehnike.
R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB, and (NRARB)carbonyl; A is 
Ri, R2, i Rs su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NR,R; i (NRaRe)karbonila;
The process according to claim 7, characterized in that the reaction is carried out at a temperature from 140°C to 170°C. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da se reakcija provodi pri temperaturi od 140 °C do 170 °C.
substitution of amino acid 951: in protein E2; to isoleucine. 
supstituciju aminokiseline 951; u proteinu E2; izoleucinom. 5.
(viii) harvesting and drying the enriched microbial consortium, and 
(vli)skupljanje i sušenje obogaćene mikrobne zajednice, i
An apparatus as claimed in claim 2, wherein the channel is downwardly sloping V-shaped channel. 
Uređaj u skladu s patentnim zahtjevom 2, naznačen time što je kanal (4) kanal u obliku slova V nagnut prema dolje.
The metal substrate of statement 14, wherein the electroplated metal layer is selected from the group consisting of nickel, nickel-phosphorus, copper, brass, gold, silver, and platinum. 
Metalna podloga u skladu s patentnim zahtjevom 8, naznačen time što se galvanizirani metalni sloj bira iz skupine koju čine nikal, niklo-fosfor, bakar, mjed, zlato, srebro, te platina.
When calculated on the basis of the total weight of the composite material, the filler ingredient(s) typically constitute(s) 15-90% of the total weight of the composite material, e.g. 
Kada se računa na bazi ukupne mase kompozitnog materijala, sastojak(ci) za punjenje tipično čini 15-90% ukupne mase kompozitnog materijala, npr.
A method according to claim 2 comprising the further step determining from the received one or more acknowledgement indications the higher data rate to use when transmitting the payload data. 
određivanje iz jedne ili više zaprimljenih potvrdnih naznaka, o tome koju od većih podatkovnih brzina treba upotrijebiti, kada se vrši prijenos skupova korisničkih informacija (36).
In a seventh aspect, the invention also provides a process for the synthesis of an acid salt of N-methylcyclopentylamine, the process comprising the reductive amination of cyclopentanone in the presence of an acid salt of methylamine. 
Postupak sinteze spoja u skladu s patentnim zahtjevom 1, naznačen time što se postupak sastoji u postupku sinteze kisele soli N-metilciklopentilamina, gdje postupak uključuje reduktivno aminiranje ciklopentanona u prisutnosti kisele soli metilamina.
The figure shows the expansion of the elution peak, collected in 3 ml fractions. 
Na slici je prikazana ekspanzija peak-a eluacije, sakupljenog u tri frakcije.
An aqueous solution comprising Compound 1 and at least 5 zinc ions per insulin hexamer. 
Vodena otopina prema patentnom zahtjevu 7, koja sadrži najmanje 5 iona cinka po heksameru inzulina.
A blank to obtain a cigarette box, according to the invention, with a hinged lid in the shape of a rectangular prism, formed of a storage part adapted to accommodate cigarettes within and a hinged lid connected with said storage part by means of an articulated joint located on the rear wall, where the front wall of the lid is longer than its rear wall, and the side walls are oblique. 
Shema za izradu kutije za cigarete, prema izumu, sa preklopnim poklopcem u obliku pravokutne prizme, sastavljene od spremišnog dijela namijenjenog za držanje cigareta, 1 preklopnog poklopca spojenog s navedenim spremišnim dijelom pomoću zglobnog spoja koji se nalazi na stražnjem zidu, gdje je prednji zid poklopca duži od njegovog stražnjeg zida i bočni zidovi su kosi.
Use according to claim 17, characterized in that following addition of said 2-((1-methylpropyl)amino)ethanol to said suspension, the suspension is passed through a passage having a suspension throughput regulated as a function of the suspension conductivity. 
HR P20161356 T1 19.Postupak u skladu s patentnim zahtjevom 17, naznačen time da nakon dodavanja navedenog 2-((1- metilpropil)aminojetanola u navedenu suspenziju, suspenzija prolazi kroz prolaz koji ima protok otopine reguliran kao funkciju vodljivosti suspenzije.
Use of lactose is preferred. 
Poželjna je uporaba laktoze.
The use according to claim 18, wherein the disease or condition is pseudobulbar affect. 
Uporaba u skladu s patentnim zahtjevom 18, pri čemu je bolest ili stanje pseudobulbarni afekt.